Ascend Wellness Holdings Q3 2026 Earnings Conference Call - VITRIA TECHNOLOGY INC

Explicit Guidance:

• Q4 2026 Revenue: Expected growth of approximately 1% to 2% sequentially, driven by new store ramp-ups and M&A pipeline, offset by seasonal discounting and continued price compression.
• Q4 2026 Margins: Adjusted EBITDA margins expected to remain similar to Q3 levels (23.9%).
• Full-Year 2026 CapEx: Total expected at approximately $20 million; $15.7 million deployed YTD, with remaining funds allocated to new store openings and maintenance CapEx for cultivation/manufacturing facilities.
• M&A Capital Availability: Secured $11 million in non-dilutive mortgage financing (8.5% interest, maturing Oct 2031) to support retail densification and M&A activities.

Business-Segment Outlook:

• Retail Footprint: Target of 60 stores exceeded; currently at 61 stores (including partner locations) post-quarter end. No specific FY2027 store count guidance provided, but management remains "relentless" in pursuing M&A to densify core markets.
• Geography:
  • New Jersey: Two delayed partner store opportunities expected to open early 2027, bringing the state footprint to 9 locations.
  • Massachusetts: Operating 2 new locations (Worcester/Shrewsbury) pending acquisition closure; upon closing, plans to extend vertically integrated medical licenses to all 10+ MA stores and the Nathall facility.
  • Ohio: Expanded to 7 stores with the recent Lewis Center opening.
  • Illinois: Partner opened a 17th location in Plano; wholesale operations recovering from July strike, with September sales at record levels.
• Product & Brand Strategy: Focus on scaling house brands and optimizing SKU count rather than maximizing volume.
  • Ozone: Premium flour lineup expansion (Ozone Signature) launched in core markets.
  • Simply Herb: Vape flavor expansion driving rank improvement; new fast-acting gummy formulas and F&Tabs (THC tablets) launched in NJ, MA, and IL.
  • High Wired: Infused flower/pre-roll categories growing at ~2x category rate; new Honor Roll formats (glass tip, 10-pack, 2-pack) launching later in Q3.
• Wholesale Channel: Intentional reduction in wholesale dependence as retail verticalization increases; wholesale revenue decline attributed to shift of biomass sales into higher-margin retail channels.

Market and Competitive Outlook:

• Regulatory Inflection: Anticipate meaningful demand shift from unregulated "intoxicating hemp" to the regulated market following the federal loophole closure deadline (moved to Dec 11), potentially accelerating in states with early bans.
• Competitive Position: Ascend holds #2 brand house position in IL, NJ, and MA combined; aiming to be #1 in every core market. NJ market share increased ~14% QoQ.
• Pricing Environment: Expect continued price compression in Q4 and beyond; management remains conservative on pricing assumptions due to seasonal promotional pressure in Q4.
• International Expansion: First time bringing brands to Canada via licensing with Atlantic Cultivation; "High Wired Infused Pre-Rolls" and "Ozone Liquid Vapes" expected on shelves in Q1 2027. No financial projections included for this initiative yet.

Macro / Industry Outlook:

• Federal Cannabis Rescheduling: DEA hearing concluded July 2026; recommendation pending. Management views this as a procedural step with no impact on existing state medical reclassifications.
• State-Level Durability: Cites Massachusetts voter rejection of adult-use repeal (75% "No") as evidence of long-term market durability.
• Economic Impact: Interest payments (biannual) pressure Q1/Q3 cash flow; management prioritizes consistent cash flow generation to navigate capital costs.

Strategic Initiatives:

• Capital Allocation: Utilization of $11 million mortgage financing for non-dilutive expansion; maintaining high bar for M&A returns (targeting >30% ROIC).
• Operational Efficiency: Yield improvements of 21% since Q1 2025; focus on "hubs and spokes" model to drive operating leverage and vertical integration.
• Capital Markets: Shareholders approved reverse stock split in Aug 2026; timing contingent on eligibility for uplisting to a major U.S. exchange.
• Technology: Rolling out contactless "tap-to-pay" across the network; "Ascend Pay" adoption at >11% of transactions.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Timing and outcome of federal rescheduling remain uncertain.
• Market Dynamics: Continued price compression and seasonal promotional pressure could dampen Q4 top-line growth despite store additions.
• Operational Risks: State-level regulatory delays (e.g., NJ partner stores) and potential shifts in hemp loopholes.
• Cost Pressures: General inflation or cost increases could impact SG&A and CapEx efficiency.
• Wholesale Dependence: While reducing reliance, a rapid shift in channel mix could cause temporary revenue volatility during the transition.

Management Tone on the Future:

• Confidence: High confidence in momentum, citing "strong execution" across all strategic pillars (retail densification, customer experience, CPG strategy).
• Milestones: Proud of exceeding the 60-store target ahead of schedule and achieving positive operating cash flow despite interest payments.
• Future Outlook: Viewed as "encouraged" by densification strategy; committed to chasing #1 market share status in all core territories.
• Cautious Optimism: Guidance for Q4 is described as "conservative but realistic" regarding pricing and seasonal trends.

Miscellaneous:

• Store Economics: Current M&A acquisitions performing in line with conservative underwriting assumptions; payback period driven by vertical integration synergies.
• Loyalty: Loyalty members account for 86% of transactions; average ticket held steady despite price compression.
• ESG/Social: Partnered with a social equity partner for the Malton, NJ opening.